fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Dolutegravir

All products: general benefit

Tivicay · DIN 02414945 · 50 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

ViiV Supports Patient Support Program

Manufacturer assistance may reduce out-of-pocket costs. It is not subtracted from public estimates. Final out-of-pocket cost is not established.

1-855-525-5300·Canadian ViiV support and registration

Conditions and dated sources

Manufacturer assistance may reduce out-of-pocket costs. If this ViiV medication is prescribed and cost is a barrier, ask your pharmacist about ViiV Supports. Canadian residence and a valid prescription are required; the program assesses financial need.

The amount, maximum, duration and detailed financial eligibility have not been confirmed. Assistance is not guaranteed.

A Trillium deductible interaction is not stated in the public materials checked. Ask ViiV Supports and the pharmacist to confirm. No assistance is subtracted from public estimates.

Ask your pharmacist about ViiV Supports, or call the Canadian program before registering. It can help check public and private coverage options.

A valid prescription for a participating ViiV product is required. A product match does not establish the reason it was prescribed or financial eligibility.

The current welcome page states Monday to Friday, 8 am to 8 pm EST; confirm availability with the program.

Possible temporary financial assistance at the manufacturer's discretion; eligibility is not guaranteed and support may change or end.

“The program offers reimbursement navigation services to assist patients in obtaining public and/or private coverage.” June 2026, code PM-CA-HVX-WCNT-260001; accessed 2026-09-18

“Your eligibility in the Program is not guaranteed” Undated current linked terms, pages 1-2; accessed 2026-09-18

1 brand, same coverage
Tivicay · DIN 02414945 Manufacturer: ViiV Healthcare ULC; listing date 2015-04-30 Health Canada: Marketed since 2013-11-08 · brand TIVICAY · ATC J05AJ03 DOLUTEGRAVIR · form Tablet · route Oral · ingredients DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG · company Viiv healthcare ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $12.9452 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02414945)

Source record
DIN 02414945: Tivicay Raw flags: sec3=Y Item: 081800373; group id 73; item number 0141; lccId None; manufacturer id VIH Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $23.9840; ministry $12.9452 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02414945 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89957
Interchangeable products
PMS-Dolutegravir · DIN 02556782 · $12.9452
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02414945
Shortage record checked October 6, 2026

Other products in the same Health Canada class (J05A, J05AJ): coverage varies; not interchangeable

  • Cabotegravir (Apretude): general benefit
  • Raltegravir (Isentress): general benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir (Ziagen): general benefit
  • Abacavir + lamivudine (Kivexa): general benefit
  • Acyclovir (Zovirax): general benefit, not a benefit

48 more in the class list below

Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab

RALTEGRAVIR POTASSIUM

· 2 products · General benefit · strengths: 400mg, 600mg · Tab

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit

COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 150mg & 150mg & 200mg & 300mg · Tab

DARUNAVIR

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 600mg, 800mg · Tab

DARUNAVIR & COBICISTAT

· 1 products · General benefit · strengths: 800mg & 150mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications TIVICAY, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adults and in INSTI-naïve pediatric patients aged 4 weeks and older and weighing at least 3 kg. 1.1 Pediatrics Pediatrics (aged less than 4 weeks or weighing less than 3 kg or INSTI-experienced): Safety and efficacy of TIVICAY have not been established in children aged less than 4 weeks or weighing less than 3 kg or who are INSTI-experienced with documented or clinical suspected resistance to other INSTIs. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Clinical studies of TIVICAY did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from adult patients < 65 years of age. https://pdf.hres.ca/dpd_pm/00082179.PDF PM date: 2025-10-24 Source product: TIVICAY; DIN 02414945; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.